Development of a Generic PBK Model for Human Biomonitoring with an Application to Deoxynivalenol

Toxins (Basel). 2023 Sep 13;15(9):569. doi: 10.3390/toxins15090569.

Abstract

Toxicokinetic modelling provides a powerful tool in relating internal human exposure (i.e., assessed through urinary biomarker levels) to external exposure. Chemical specific toxicokinetic models are available; however, this specificity prevents their application to similar contaminants or to other routes of exposure. For this reason, we investigated whether a generic physiological-based kinetic (PBK) model might be a suitable alternative for a biokinetic model of deoxynivalenol (DON). IndusChemFate (ICF) was selected as a generic PBK model, which could be fit for purpose. Being suited for simulating multiple routes of exposure, ICF has particularly been used to relate the inhalation and dermal exposure of industrial chemicals to their urinary excretion. For the first time, the ICF model was adapted as a generic model for the human biomonitoring of mycotoxins, thereby extending its applicability domain. For this purpose, chemical-specific data for DON and its metabolites were collected directly from the literature (distribution and metabolism) or indirectly (absorption and excretion) by fitting the ICF model to previously described urinary excretion data. The obtained results indicate that this generic model can be used to model the urinary excretion of DON and its glucuronidated metabolites following dietary exposure to DON. Additionally, the present study establishes the basis for further development of the model to include an inhalation exposure route alongside the oral exposure route.

Keywords: deoxynivalenol; deoxynivalenol-15-glucuronide; deoxynivalenol-3-glucuronide mycotoxin; dietary exposure; generic PBK modelling; human biomonitoring; renal excretion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biological Monitoring*
  • Body Fluids*
  • Dietary Exposure
  • Humans
  • Kinetics

Substances

  • deoxynivalenol

Grants and funding

This research was funded by the Horizon 2020 Research and Innovation Program under grant agreement no 733032, HBM4EU.